Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Net Margin (2020 - 2025)

Vivos Therapeutics has reported Net Margin over the past 6 years, most recently at 181.85% for Q4 2025.

  • Quarterly Net Margin fell 10540.0% to 181.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 121.72% through Dec 2025, down 4763.0% year-over-year, with the annual reading at 121.71% for FY2025, 4762.0% down from the prior year.
  • Net Margin was 181.85% for Q4 2025 at Vivos Therapeutics, down from 79.61% in the prior quarter.
  • Over five years, Net Margin peaked at 44.15% in Q1 2023 and troughed at 181.85% in Q4 2025.
  • The 5-year median for Net Margin is 123.97% (2021), against an average of 114.82%.
  • Year-over-year, Net Margin skyrocketed 17743bps in 2021 and then tumbled -10540bps in 2025.
  • A 5-year view of Net Margin shows it stood at 168.25% in 2021, then rose by 8bps to 154.15% in 2022, then rose by 15bps to 131.13% in 2023, then soared by 42bps to 76.45% in 2024, then tumbled by -138bps to 181.85% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Net Margin are 181.85% (Q4 2025), 79.61% (Q3 2025), and 131.23% (Q2 2025).